TY - JOUR
T1 - The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer
T2 - The need trial
AU - Botticelli, Andrea
AU - Mezi, Silvia
AU - Pomati, Giulia
AU - Sciattella, Paolo
AU - Cerbelli, Bruna
AU - Roberto, Michela
AU - Mammone, Giulia
AU - Cirillo, Alessio
AU - Cassano, Alessandra
AU - Dio, Carmela Di
AU - Cortellini, Alessio
AU - Pizzuti, Laura
AU - Ronzino, Graziana
AU - Salati, Massimiliano
AU - Vici, Patrizia
AU - Polimeni, Antonella
AU - Merlano, Marco Carlo
AU - Nuti, Marianna
AU - Marchetti, Paolo
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - Background: Previous locoregional treatment could affect the response to nivolumab in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The aim of this study is to evaluate the impact of the clinicopathological characteristics and previous treatment in predicting early progression to nivolumab in a real-world population. Methods: This is an observational, multicenter retrospective/prospective study including patients (pts) with platinum refractory R/M HNSCC who received nivolumab 240 mg every 2 weeks from October 2018 to October 2019. We analyzed the association between previous treatment, clinicopathological characteristics, and early progression (within 3 months). Results: Data from 61 pts were reviewed. Median age was 67 years (30–82). Forty-two pts (69%) received previous locoregional treatment. Early progression to nivolumab occurred in 36 pts (59%), while clinical benefit (stable disease and partial response) was achieved in 25 pts (41%). Early progression to nivolumab was significantly associated to previous locoregional treatment both at univariate and multivariate analysis (p = 0.005 and p = 0.048, respectively). Conclusion: nivolumab in R/M HNSCC is burdened with a high early progression rate. Previous wide neck dissection and high dose radiotherapy may compromise the efficacy of nivolumab, distorting the anatomy of the local lymphatic system and hindering the priming of immune response.
AB - Background: Previous locoregional treatment could affect the response to nivolumab in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The aim of this study is to evaluate the impact of the clinicopathological characteristics and previous treatment in predicting early progression to nivolumab in a real-world population. Methods: This is an observational, multicenter retrospective/prospective study including patients (pts) with platinum refractory R/M HNSCC who received nivolumab 240 mg every 2 weeks from October 2018 to October 2019. We analyzed the association between previous treatment, clinicopathological characteristics, and early progression (within 3 months). Results: Data from 61 pts were reviewed. Median age was 67 years (30–82). Forty-two pts (69%) received previous locoregional treatment. Early progression to nivolumab occurred in 36 pts (59%), while clinical benefit (stable disease and partial response) was achieved in 25 pts (41%). Early progression to nivolumab was significantly associated to previous locoregional treatment both at univariate and multivariate analysis (p = 0.005 and p = 0.048, respectively). Conclusion: nivolumab in R/M HNSCC is burdened with a high early progression rate. Previous wide neck dissection and high dose radiotherapy may compromise the efficacy of nivolumab, distorting the anatomy of the local lymphatic system and hindering the priming of immune response.
KW - Head and neck cancer
KW - Immunotherapy
KW - Locoregional treatment
KW - Nivolumab
KW - Squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85083830456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083830456&partnerID=8YFLogxK
U2 - 10.3390/vaccines8020191
DO - 10.3390/vaccines8020191
M3 - Article
AN - SCOPUS:85083830456
VL - 8
JO - Vaccines
JF - Vaccines
SN - 2076-393X
IS - 2
M1 - 191
ER -